Literature DB >> 7830891

Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system.

A Kastner1, P Anglade, C Bounaix, P Damier, F Javoy-Agid, N Bromet, Y Agid, E C Hirsch.   

Abstract

The cellular localization of catechol-O-methyltransferase was analysed in the mesostriatal system of human brain post mortem by means of immunohistochemistry. In the human nigral complex, catechol-O-methyltransferase immunostaining was not detected in melanized dopaminergic neurons, except in the ventral tegmental area and substantia nigra pars lateralis, where few neurons displayed intense immunolabelling. In the striatum, catechol-O-methyltransferase immunostaining was found in numerous cell bodies and in the neuropile. Observations at the electron microscope level revealed that catechol-O-methyltransferase immunoreactivity was present in the cell bodies of neurons and their processes, including the dendritic spines. No catechol-O-methyltransferase immunolabelling was observed in striatal nerve terminals in contact with dendritic spines, indicating that dopaminergic nerve terminals do not exhibit catechol-O-methyltransferase immunoreactivity. Catechol-O-methyltransferase-immunoreactive cell bodies and processes of glial cells were also detected in the striatum. The data suggest that catechol-O-methyltransferase is either not expressed or only slightly expressed by the dopaminergic nigrostriatal neurons, whereas it is clearly present in striatal neurons and glial cells. Thus, the catabolic degradation of striatal released dopamine by its O-methylation may involve postsynaptic neurons rather than dopaminergic presynaptic neurons. The presence of catechol-O-methyltransferase in some dopaminergic neurons of the ventral tegmental area and substantia nigra pars lateralis suggests that methylation of dopamine may occur in these neurons, which may consequently be better protected against dopamine auto-oxidation than those of the substantia nigra pars compacta.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7830891     DOI: 10.1016/0306-4522(94)90379-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

1.  Astrocyte-neuron interactions in neurological disorders.

Authors:  G Ricci; L Volpi; L Pasquali; L Petrozzi; G Siciliano
Journal:  J Biol Phys       Date:  2009-05-14       Impact factor: 1.365

2.  Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.

Authors:  Torun Malmlöf; Kristin Feltmann; Åsa Konradsson-Geuken; Frank Schneider; Rudolf-Giesbert Alken; Torgny H Svensson; Björn Schilström
Journal:  J Neural Transm (Vienna)       Date:  2014-06-07       Impact factor: 3.575

3.  The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.

Authors:  M Gerlach; A Y Xiao; W Kuhn; R Lehnfeld; P Waldmeier; K H Sontag; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

4.  COMT influences on prefrontal and striatal blood oxygenation level-dependent responses during working memory among individuals with schizophrenia, their siblings, and healthy controls.

Authors:  Alan Ceaser; John G Csernansky; Deanna M Barch
Journal:  Cogn Neuropsychiatry       Date:  2012-10-03       Impact factor: 1.871

5.  Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets.

Authors:  Bai-Yun Zeng; Robert H Balfour; Mike J Jackson; Sarah Rose; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2009-09-22       Impact factor: 3.575

Review 6.  Executive function, neural circuitry, and genetic mechanisms in schizophrenia.

Authors:  Daniel Paul Eisenberg; Karen Faith Berman
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.

Authors:  Alipi V Naydenov; Fair Vassoler; Andrew S Luksik; Joanna Kaczmarska; Christine Konradi
Journal:  Acta Neuropathol       Date:  2010-08-26       Impact factor: 17.088

8.  COMT val158met polymorphism and molecular alterations in the human dorsolateral prefrontal cortex: Differences in controls and in schizophrenia.

Authors:  Abhay A Shukla; Manish Jha; Thomas Birchfield; Shibani Mukherjee; Kelly Gleason; Salim Abdisalaam; Aroumougame Asaithamby; Beverley Adams-Huet; Carol A Tamminga; Subroto Ghose
Journal:  Schizophr Res       Date:  2016-03-24       Impact factor: 4.939

9.  Catechol-O-methyltransferase genotype and dopamine regulation in the human brain.

Authors:  Mayada Akil; Bhaskar S Kolachana; Debora A Rothmond; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

10.  Poor evidence for depolarization block but uncoupling of nigral from striatal dopamine metabolism after chronic haloperidol treatment in the rat.

Authors:  S J Chrapusta; M F Egan
Journal:  J Neural Transm (Vienna)       Date:  2005-08-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.